Absorbed dose distributions in patients with bone metastases from hormone refractory prostate cancer treated with Re-186 HEDP

被引：0
|
作者：
Bacelar, A. M. Denis [1 ]
Divoli, A. [2 ]
Chittenden, S. [2 ]
Du, Y. [2 ]
Dearnaley, D. P. [1 ]
O'Sullivan, J. M. [3 ]
Flux, G. D. [2 ]
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Royal Marsden Hosp, Sutton, Surrey, England
[3] Queens Univ Belfast, Belfast City Hosp, Belfast, Antrim, North Ireland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S188 / S188
页数：1
相关论文
共 50 条
  • [1] Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases
    N. Ö. Küçük
    E. İbiş
    G. Aras
    S. Baltaci
    G. Özalp
    Y. Bedük
    N. Çanakci
    A. Soylu
    Annals of Nuclear Medicine, 2000, 14 : 239 - 245
  • [2] PHARMACOKINETICS OF RE-186 AFTER ADMINISTRATION OF RHENIUM-186-HEDP TO PATIENTS WITH BONE METASTASES
    DEKLERK, JMH
    VANDIJK, A
    VANHETSCHIP, AD
    ZONNENBERG, BA
    VANRIJK, PP
    JOURNAL OF NUCLEAR MEDICINE, 1992, 33 (05) : 646 - 651
  • [3] Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP
    Palmedo, H
    Grunwald, F
    Wagner, U
    Kohler, S
    Krebs, D
    Biersack, HJ
    CLINICAL NUCLEAR MEDICINE, 1998, 23 (08) : 501 - 504
  • [4] PHARMACOKINETICS OF RE-186 AFTER ADMINISTRATION OF RHENIUM-186-HEDP TO PATIENTS WITH BONE METASTASES AND MEANING OF THE BONE-SCAN INDEX
    DEKLERK, JMH
    VANDIJK, A
    SCHIP, ADV
    HAKMAN, ME
    ZONNENBERG, BA
    VANRIJK, PP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1992, 19 (08): : 623 - 623
  • [5] Re-186HEDP treatment in breast cancer patients with bone metastases
    Koutsikos, John
    Leondi, Anastasia
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2008, 100 (04) : 447 - 447
  • [6] RE-186(SN) HEDP FOR TREATMENT OF PAINFUL OSSEOUS METASTASES - INITIAL CLINICAL-EXPERIENCE IN 20 PATIENTS WITH HORMONE-RESISTANT PROSTATE-CANCER
    MAXON, HR
    SCHRODER, LE
    THOMAS, SR
    HERTZBERG, VS
    DEUTSCH, EA
    SCHER, HI
    SAMARATUNGA, RC
    LIBSON, KF
    WILLIAMS, CC
    MOULTON, JS
    SCHNEIDER, HJ
    RADIOLOGY, 1990, 176 (01) : 155 - 159
  • [7] High activity therapy for bone metastases from CA prostate using Re-186 HEDP and peripheral blood stem cell support
    McCready, VR
    David, D
    Trelevan, J
    Al-Deen, A
    RADIOLOGY, 1998, 209P : 438 - 438
  • [8] Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases
    Zafeirakis, Athanasios
    Papatheodorou, Georgios
    Arhontakis, Athanasios
    Gouliamos, Athanasios
    Vlahos, Lambros
    Limouris, Georgios S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (01) : 103 - 113
  • [9] Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases
    Athanasios Zafeirakis
    Georgios Papatheodorou
    Athanasios Arhontakis
    Athanasios Gouliamos
    Lambros Vlahos
    Georgios S. Limouris
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 103 - 113
  • [10] Metastatic control probability in patients with prostate cancer metastatic to bone treated 186Re-HEDP
    Denis-Bacelar, A. M.
    Divoli, A.
    Chittenden, S.
    Du, Y.
    Flux, G. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S58 - S58
12345